You just read:

Multimedia Assets Now Available: FDA Approves Eisai's LENVIMA® (lenvatinib) for the Treatment of Patients with Advanced Renal Cell Carcinoma in Combination with Everolimus Following Prior Anti-Angiogenic Therapy

News provided by

Eisai Inc.

May 16, 2016, 08:08 ET